CYP2C9 Substrates
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Diclofenac Sodium | 15307-79-6 | sc-202136 sc-202136A | 5 g 25 g | $40.00 $125.00 | 4 | |
Diclofenac Sodium acts as a substrate for CYP2C9, showcasing unique interactions that influence its metabolic fate. The compound's carboxylic acid moiety allows for ionic interactions with the enzyme, while its aromatic structure promotes hydrophobic interactions, enhancing binding affinity. The presence of multiple functional groups facilitates diverse metabolic pathways, leading to the formation of various metabolites. Its stereochemistry also plays a crucial role in determining the enzyme's selectivity and reaction kinetics. | ||||||
Idarubicin Hydrochloride | 57852-57-0 | sc-204774 sc-204774A sc-204774B sc-204774C | 1 mg 5 mg 10 mg 50 mg | $72.00 $170.00 $269.00 $740.00 | 2 | |
Idarubicin Hydrochloride interacts with CYP2C9 through specific hydrogen bonding and hydrophobic interactions, which are influenced by its planar aromatic system. The compound's unique structural features, including its hydroxyl and amine groups, facilitate complex formation with the enzyme, affecting its metabolic stability. Additionally, the stereochemical configuration of Idarubicin can alter the enzyme's catalytic efficiency, leading to distinct metabolic profiles and reaction kinetics. | ||||||
Ticrynafen | 40180-04-9 | sc-220253 | 10 mg | $296.00 | ||
Ticrynafen exhibits notable interactions with CYP2C9, characterized by its ability to form stable complexes through electrostatic and van der Waals forces. The presence of halogen substituents enhances its lipophilicity, promoting efficient binding to the enzyme's active site. This compound's unique conformation allows for selective orientation during metabolism, influencing the rate of enzymatic reactions and leading to varied metabolic pathways. Its distinct electronic properties further modulate enzyme activity, impacting overall kinetics. | ||||||
S-(−)-Warfarin-d5 | 5543-57-7 (unlabeled) | sc-474151 | 1 mg | $380.00 | ||
S-(-)-Warfarin-d5 demonstrates intriguing interactions with CYP2C9, primarily through hydrogen bonding and hydrophobic interactions that stabilize its binding to the enzyme. The deuterated form alters kinetic isotope effects, providing insights into metabolic pathways. Its unique stereochemistry influences substrate specificity, while the presence of deuterium enhances stability and reduces metabolic turnover. This compound's distinct electronic distribution also plays a role in modulating enzyme affinity and activity. | ||||||
(S)-(−)-Warfarin | 5543-57-7 | sc-253488B sc-253488 sc-253488A sc-253488C sc-253488D | 1 mg 5 mg 10 mg 25 mg 50 mg | $168.00 $515.00 $740.00 $1637.00 $2861.00 | ||
(S)-(-)-Warfarin exhibits notable characteristics when interacting with CYP2C9, particularly through its chiral configuration, which affects enzyme selectivity and binding affinity. The compound's electron-withdrawing groups enhance its reactivity, facilitating specific metabolic transformations. Additionally, its conformational flexibility allows for dynamic interactions within the active site, influencing reaction kinetics. The presence of substituents further modulates the enzyme's catalytic efficiency, showcasing the complexity of its metabolic behavior. | ||||||